ABZORVE
Live / Registered — Registered (as of 06 Jan 2026)
What this means for you
Registered since 06 Jan 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99203958
- Registration number
- 8094132
- Mark type
- Stylized text
- Filed
- 27 May 2025
- Published for opposition
- 18 Nov 2025
- Registered
- 06 Jan 2026
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Anti-infectives; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 06 Jan 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 06 Jan 2026 — REGISTERED-PRINCIPAL REGISTER
- 18 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Nov 2025 — PUBLISHED FOR OPPOSITION
- 12 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 15 Sept 2025 — ASSIGNED TO EXAMINER
- 27 May 2025 — APPLICATION FILING RECEIPT MAILED
- 27 May 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 27 May 2025 — NEW APPLICATION ENTERED